Measurement of somatostatin receptor subtype 2 mRNA breast cancer and corresponding normal tissue

Endocrine-Related Cancer

Volumn 11, Issue 2, 2004, Pages 323-332

  Orlando, C ^a   Raggi, C Casini ^a   Bianchi, S ^a   Distante, V ^a   Simi, L ^a   Vezzosi, V ^a   Gelmini, S ^a   Pinzani, P ^a   Smith, M Cameron ^a   Buonamano, A ^a   Lazzeri, E ^a   Pazzagli, M ^a   Cataliotti, L ^a   Maggi, M ^a   Serio, M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; MESSENGER RNA; PROGESTERONE RECEPTOR; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 2;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CANCER INHIBITION; CELL MEMBRANE; CELL PROLIFERATION; CLINICAL FEATURE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL; CARCINOMA, LOBULAR; CELL PROLIFERATION; FEMALE; HUMANS; IN SITU HYBRIDIZATION; LYMPH NODES; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECEPTORS, SOMATOSTATIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 3042587319     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0110323     Document Type: Article

References (56)

1. Bajetta E, Procopio G, Ferrari L, Martinetti A, Zilembo N, Catena L, Alu M, Della TS, Alberti D & Buzzoni R 2002 A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. Cancer 94 299-304.
2. Balaton AJ 1999 Recommandations pour l'évaluation immunohistochimique des récepteurs hormonaux sur coupes en paraffine dans les carcinomes mammaires. Mise à jour 1999. Annales de Pathologie 19 336-343.
3. Benali N, Cordelier P, Calise D, Pages P, Rochaix P, Nagy A, Esteve JP, Pour PM, Schally AV, Vaysse N, Susini C & Buscail L 2000 Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. PNAS 97 9180-9185.
4. Bouzubar N, Walker KJ, Griffiths K, Ellis IO, Elston CW, Robertson JFR, Blamey WW & Nicholson RI 1989 Ki-67 immunostaining in primary breast cancer: pathological and clinical associations. British Journal of Cancer 59 943-947.
5. Briganti V, Sestini R, Orlando C, Bernini G, La Cava G, Tamburini A, Casini Raggi C, Serio M & Maggi M 1997 Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor 2 gene expression in neuroblastoma tumors. Clinical Cancer Research 3 2385-2391.
6. Buscail L, Esteve J-P, Saint-Laurent N, Bertrand V, Reisine T, O'Carrol AM, Bell GI, Liebow C, Schally A, Vaysse N & Susini C 1995 Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by SSTR2 and SSTR5 somatostatin receptors through different mechanisms. PNAS 92 1580-1584.
7. Casini Raggi C, Maggi M, Renzi D, Calabrò A, Bagnoni ML, Scaruffi P, Tonini GP, Pazzagli M, De Bernardi B, Bernini G, Serio M & Orlando C 2000 Quantitative determination of sst2 gene expression in neuroblastoma tumor predicts patient outcome. Journal of Clinical Endocrinology and Metabolism 85 3866-3873.
8. Casini Raggi C, Calabrò A, Renzi D, Briganti V, Cianchi F, Messerini L, Valanzano R, Cameron Smith M, Cortesini C, Tonelli F, Serio M, Maggi M & Orlando C 2002 Quantitative evaluation of somatostatin receptor subtype 2 expression in sporadic colorectal tumor and in the corresponding normal mucosa. Clinical Cancer Research 8 419-427.
9. Elston CW & Ellis IO 1991 Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19 403-410.
10. EORTC 1980. Breast Cooperative Group. Revision of the standards for the assessment of hormone receptors in human breast cancer. Report of the second EORTC workshop. European Journal of Cancer 6 1513-1515.
11. Evans AA, Crook T, Laws SAM, Gough AC, Royle GT & Primrose JN 1997 Analysis of somatostatin receptor subtype mRNA expression in human breast cancer. British Journal of Cancer 75 798-803.
12. Foekens JA, van Putten WL, Portengen H, Rodenburg CJ, Reubi JC, Berns PM, Henzen-Logmans SC, van der Burg ME, Alexieva-Figusc J & Klijn JG 1990 Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer. Journal of Steroid Biochemistry and Molecular Biology 37 815-821.
13. Harris J, Morrow M & Norton L 1997 Malignant tumors of the breast. In Cancer, Principles and Practice of Oncology, 5th edn, pp 1557-1616. Eds VT De Vita Jr, S Hellman & SA Rosenberg. Philadelphia: Lippincott-Raven.
14. Ingle JN, Suman VJ, Kardinal CG, Krook JE, Mailliard JA, Veeder MH, Loprinzi CL, Dalton RJ, Hartmann LC, Conover CA & Pollak MN 1999 A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer 85 1284-1292.
15. Jenkins SA, Kynaston HG, Davies ND, Baxter JN & Nott DM 2001 Somatostatin analogs in oncology: a look to the future. Chemotherapy 47 162-196.
16. Kimura N, Tomizawa S, Arai KN, Osamura RY & Kimura N 2001 Characterization of 5′-flanking region of rat somatostatin receptor sst2 gene: transcriptional regulatory elements and activation by Pitx1 and estrogen. Endocrinology 142 1427-1441.
17. 111In-octreotide scintigraphy in oncology. Digestion 54 84-87.
18. Manni A, Boucher AE, Demers LM, Harvey HA, Lipton A, Simmonds MA & Bartholomew M 1989 Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer. Breast Cancer Research and Treatment 14 289-298.
19. McCarthy KE, Woltering EA, Espenan GD, Cronin M, Maloney TJ & Anthony LB 1998 In situ radiotherapy with 111In-pentetreotide: initial observations and future considerations. Cancer Journal 4 94-102.
20. Nagy A, Schally AV, Halmos G, Armatis P, Cai R-Z, Csernus V, Kovacs M, Koppan M, Szepeshazi K & Kahan Z 1998 Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolin-doxorubicin. PNAS 95 1794-1799.
21. Nass SJ & Davidson NE 1999 The biology of breast cancer. Hematology/Oncology Clinics of North America 13 311-327.
22. Nelson J, Cremin M & Murphy RF 1989 Synthesis of somatostatin by breast cancer cells and their inhibition by exogenous somatostatin and sandostatin. British Journal of Cancer 59 739-742.
23. O'Byrne KJ, Dobbs N, Propper DJ, Braybrooke JP, Koukourakis MI, Mitchell K, Woodhull J, Talbot DC, Schally AV & Harris AL 1999 Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer. British Journal of Cancer 79 1413-1418.
24. Pagliacci MC, Tognellini R, Grignani F & Nicoletti I 1991 Inhibition of human breast cancer cell (MCF7) growth in vitro by the somatostatin analogue SMS201-995: effects on cell cycle parameters and apoptotic cell death. Endocrinology 129 255-256.
25. Papotti M, Macri L, Bussolati G & Reubi J 1989 Correlative study on neuroendocrine differentiation and presence of somatostatin receptors in breast carcinomas. International Journal of Cancer 43 365-369.
26. Patel YC & Srikant C 1997 Somatostatin receptors. Trends in Endocrinology and Metabolism 8 398-405.
27. Pilichowska M, Kimura N, Suzuki A, Yoshida R, Schindler M & Nagura H 2001 Clinicopathological value of somatostatin type 2A and estrogen receptor immunoreactivity in human breast carcinoma. Endocrine Pathology 12 55-61.
28. TM technology. Regulatory Peptides 99 79-86.
29. Prevost G, Foehrle E, Thomas F, Pihan I, Veber N, Starzec A & Israel L 1991 Growth of human breast cancer cells inhibited by the somatostatin analogue BIM23014 (somatuline). Endocrinology 128 323-330.
30. Prevost G, Provost P, Salle V, Lanson M & Thomas F 1993 A cross-linking assay allows the detection of receptors for the somatostatin analogue lanreotide in human breast tumours. European Journal of Cancer 29 1589-1592.
31. Reubi J & Torhorst J 1989 The relationship between somatostatin, epidermal growth factor and steroid hormone receptors in breast cancer. Cancer 64 1254-1260.
32. Reubi J, Waser B, Foekens J, Klijn J, Lamberts S & Laissue J 1990 Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: relationship to EGF receptors. International Journal of Cancer 46 416-420.
33. Reubi JC, Schaer JC, Waser B & Mengod G 1994 Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Research 54 3455-3459.
34. Reubi JC, Waser B, Schaer C & Laissue JA 2001 Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. European Journal of Nuclear Medicine 28 836-846.
35. Robbins RJ 1996 Somatostatin and cancer. Metabolism 45 98-100.
36. Romagnani P, Annunziato F, Lasagni L, Lazzeri E, Beltrame C, Francalanci M, Uguccioni M, Galli G, Cosmi L, Maurenzig L, Baggiolini M, Maggi E, Romagnani S & Serio M 2001 Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. Journal of Clinical Investigation 107 53-63.
37. Sant M, Capocaccia R, Coleman MP, Berrino F, Gatta G, Micheli A, Verdecchia A, Faivre J, Hakulinen T, Coebergh JW, Martinez-Garcia C, Forman D & Zappone A 2001 Cancer survival increases in Europe, but international differences remain wide. European Journal of Cancer 37 659-667.
38. Savouret JF, Bailly A, Misrahi M, Rauch C, Redeuilh G, Chauchereau A & Milgrom E 1991 Characterization of the hormone responsive element involved in the regulation of the progesterone receptor gene. EMBO Journal 10 1875-1883.
39. Scambia G, Benedetti Panici P, Baiocchi P, Perrone L, Iacobelli S & Mancuso S 1988 Antiproliferative effects of somatostatin and somatostatin analogue SMS201-995 on three human breast cancer cell lines. Journal of Cancer Research and Clinical Oncology 114 306-308.
40. Schaer J-C, Waser B, Mengod G & Reubi J-C 1997 Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography. International Journal of Cancer 70 530-537.
41. Schally AV & Nagy 1999 A cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. European Journal of Endocrinology 141 1-14.
42. Schulz S, Schmitt J, Wiborny D, Schmidt H, Olbricht S, Weise W, Roessner A, Gramsch C & Hollt V 1998 Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B, and sst3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies. Clinical Cancer Research 4 2047-2052.
43. Sestini R, Orlando C, Peri A, Tricarico C, Pazzagli M, Serio M, Pagani A, Bussolati G & Maggi M 1996 Quantitation of somatostatin receptor type 2 gene expression in neuroblastoma cell line and primary tumors using competitive reverse transcription-polymerase chain reaction. Clinical Cancer Research 2 1757-1765.
44. Setyono-Han B, Henkelman MS, Foekens JA & Klijn JGM 1987 Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Research 47 1566-1570.
45. Torrisani J, Bouisson M, Puente E, Capella G, Laurent-Puig P, Berger A, Vaysse N, Susini C & Buscail L 2001 Transcription of SST2 somatostatin receptor gene in human pancreatic cancer cells is altered by single nucleotide promoter polymorphism. Gastroenterology 120 200-209.
46. van Eijck CHJ, Krenning EP, Bootsma A, Oei HJ, van Pel R, Lindemans J, Jeekel J, Reubi JC & Lamberts SWJ 1994 Somatostatin-receptor scintigraphy in primary breast cancer. Lancet 343 640-643.
47. van Eijck C, Krenning E, Bootsma A, Oei H, van Pel R, Lindemans J, Jeekel J, Reubi J & Lamberts S 1994 Somatostatin-receptor scintigraphy in primary breast cancer. Lancet 343 640-643.
48. Vennin PH, Peyrat JP, Bonneterre J, Louchez MM, Harris AG & Demaille A 1989 Effect of the long-acting somatostatin analogue SMS201-995 (Sandostatin) in advanced breast cancer. Anticancer Research 9 153-156.
49. Veronese SM, Gambacorta M, Gottardi O, Scanzi F, Ferrari M & Lampertico P 1993 Proliferation index as a prognostic marker in breast cancer. Cancer 71 3926-3931.
50. Weckbecker G, Liu R, Tolcsvai L & Bruns C 1992 Antiproliferative effects of the somatostatin analogue octreotide (SMS201-995) on ZR-75-71 human breast cancer cells in vivo and in vitro. Cancer Research 52 4973-4978.
51. Woltering E, Barrie R, O'Dorisio TM, Arce D, Ure T, Cramer A, Holmes D, Robertson J & Fassler J 1990 Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. Journal of Surgical Research 50 245-251
52. Xu Y, Song J, Berelowitz M & Bruno JF 1996 Estrogen regulates somatostatin receptor subtype 2 messenger ribonucleic acid expression in human breast cancer cells. Endocrinology 137 5634-5640.
53. Xu Y, Berelowitz M & Bruno JF 1998 Characterization of the promoter region of the human somatostatin receptor subtype 2 gene and localization of sequences required for estrogen-responsiveness. Molecular and Cellular Endocrinology 139 71-77.
54. Yamada Y, Post S, Wang K, Tager H, Bell G & Seino S 1992a Cloning and functional characterisation of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract and kidney. PNAS 89 251-255.
55. Yamada Y, Reisine T, Law S, Ihara Y, Kubota A, Kagimoto S, Seino M, Bell G & Seino S 1992b Somatostatin receptors, an expanding gene family: cloning and functional characterisation of human SST3, a protein coupled to adenyl cyclase. Molecular Endocrinology 6 2136-2142.
56. Yamada Y, Kagimoto S, Kubota A, Yasuda K, Masuda K, Someya Y, Ihara Y, Li Q, Imura H, Seino S & Seino Y 1993 Cloning, functional expression and pharmacological characterisation of a fourth (hSSTR4) and fifth (hSSTR5) human somatostatin receptor subtype. Biochemical and Biophysical Research Communications 195 844-852.